|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.060 CNY | +1.00% |
|
+2.43% | -1.17% |
| Jun. 11 | Jointown Pharma Issues 1 Billion Yuan in Asset-Backed Securities | MT |
| Jun. 03 | Jointown Pharmaceutical Unit Gets Nod to Market Allergy Symptoms Treatment | MT |
Business description: Jointown Pharmaceutical Group Co., Ltd
Number of employees: 29,862
Sales by Activity: Jointown Pharmaceutical Group Co., Ltd
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
Distribution | 151B | 176B | 146B | 147B | 157B |
Industrial | 1.88B | 2.31B | 3.38B | 4.09B | 4.22B |
Retail | 1.84B | 2.26B | 2.82B | 2.97B | 2.88B |
Healthcare Segment | 384M | 290M | 275M | 329M | 466M |
Other Segment | 70.06M | 193M | 245M | 241M | 291M |
Intersegment Offset | -32.8B | -40.2B | -2.57B | -2.85B | -3.22B |
Geographical breakdown of sales: Jointown Pharmaceutical Group Co., Ltd
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
Eastern China | 35.35B | 39.75B | 42.79B | 44.59B | 48.31B |
Central China | 27.02B | 30.92B | 33.14B | 33.21B | 35.53B |
North China | 19.32B | 22.9B | 26.52B | 26.4B | 28.22B |
Southwest China | 10.81B | 12.99B | 13.22B | 13.82B | 14.47B |
Northwest China | 10.34B | 12.11B | 13.98B | 13.92B | 14.1B |
South China | 11.55B | 13.39B | 12.47B | 12.65B | 13.17B |
North East China | 7.85B | 8.19B | 7.84B | 7.02B | 7.37B |
Other Areas | 162M | 163M | 186M | 204M | 220M |
Executive Committee: Jointown Pharmaceutical Group Co., Ltd
| Manager | Title | Age | Since |
|---|---|---|---|
Wei He
CEO | Chief Executive Officer | 40 | 2022-04-22 |
Xiao Yi Xia
DFI | Director of Finance/CFO | 48 | 2023-11-14 |
Xi Zhang
IRC | Investor Relations Contact | - | 2022-04-22 |
Zhi Feng Liu
IRC | Investor Relations Contact | 43 | 2009-01-31 |
Lei Guo
PRN | Corporate Officer/Principal | 48 | 2008-10-31 |
Composition of the Board of Directors: Jointown Pharmaceutical Group Co., Ltd
| Director | Title | Age | Since |
|---|---|---|---|
Zhao Nian Liu
BRD | Director/Board Member | 66 | 2008-11-15 |
Deng Pan Liu
BRD | Director/Board Member | 48 | 2020-11-04 |
Yi Hua Gong
BRD | Director/Board Member | 48 | 2012-06-30 |
Xin Yang Lin
BRD | Director/Board Member | 61 | 2012-12-31 |
Ying Zheng Xu
CHM | Chairman | 53 | 2023-11-14 |
Qi Wang
BRD | Director/Board Member | 64 | 2008-11-15 |
Xue Song Wu
BRD | Director/Board Member | 53 | 2020-01-06 |
Chang Yun Liu
CHM | Chairman | 44 | 2020-10-31 |
Gu Liang Tang
BRD | Director/Board Member | 64 | 2020-11-04 |
Yin Di Lu
BRD | Director/Board Member | 64 | 2020-11-04 |
Holdings: Jointown Pharmaceutical Group Co., Ltd
| Name | Stocks | % | Valuation |
|---|---|---|---|
| 1,050,000 | 0.62% | 4 M $ |
Company details: Jointown Pharmaceutical Group Co., Ltd
Jointown Pharmaceutical Group Co., Ltd.
5 Longxing West Street
430051, Wuhan
+86 27 8468 3017
http://www.jztey.com
Pharmaceuticals Wholesale
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.00% | +2.43% | -5.24% | -6.08% | 3.68B | |
| +0.78% | +3.30% | +14.47% | +98.71% | 94.36B | |
| -0.91% | -2.21% | +45.16% | +149.72% | 55.23B | |
| +3.55% | +4.66% | +2.10% | +269.62% | 22.56B | |
| +1.24% | +1.30% | -14.05% | -22.35% | 8.01B | |
| -0.75% | -2.96% | -27.34% | -35.23% | 7.6B | |
| +0.72% | +0.66% | -10.56% | -27.84% | 6.66B | |
| -1.55% | -3.01% | +20.10% | +33.78% | 6.25B | |
| +0.81% | +1.22% | -0.23% | +23.95% | 5.36B | |
| +0.95% | +0.59% | +12.25% | +16.43% | 3.34B | |
| Average | +0.58% | +0.38% | +3.67% | +50.07% | 21.31B | |
| Weighted average by Cap. | +0.53% | +0.91% | +17.19% | +109.86% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 600998 Stock
- Company Jointown Pharmaceutical Group Co., Ltd
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
